ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "psoriasis and psoriatic arthritis"

  • Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting

    The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients

    Mark Berman1, Daphna Paran1, Yonatan Wolman1 and Ori Elkayam2, 1Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
  • Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting

    No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies

    Atul A. Deodhar1, Stefan Schreiber2, Kunal Gandhi3, Todd Fox4, Corine Gaillez4 and Chetan Karyekar3, 1Oregon Health & Science University, Portland, OR, 2Christian-Albrechts-Universität Kiel, Kiel, Germany, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Novartis Pharma AG, Basel, Switzerland

    Background/Purpose:  Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…
  • Abstract Number: 2765 • 2016 ACR/ARHP Annual Meeting

    Practicing What We Preach? Do Psoriatic Arthritis Patients Treated at an Academic Medical Center Meet Caspar Criteria?

    Sergio Schwartzman, Rima Abhyankar, Margaret Bogardus and Lisa Mandl, Hospital for Special Surgery, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) is an autoimmune musculoskeletal disease with protean manifestations, and therefore can be difficult to diagnose. Although no diagnostic criteria are available, the…
  • Abstract Number: 1293 • 2016 ACR/ARHP Annual Meeting

    Utility of Extremity Magnetic Resonance Imaging (eMRI) without Contrast Enhancement in Detecting Preclinical Psoriatic Arthritis

    Ashish J Mathew1, Jyoti Panwar2, Paul Bird3, Renu George4 and Debashish Danda1, 1Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, 2Christian Medical College, Vellore, India, Vellore, India, 3University of New South Wales, Sydney, Australia, Sydney, NSW, Australia, 4Dermatology, Christian Medical College, Vellore, India, Vellore, India

    Background/Purpose: Between 8-39% of patients with cutaneous psoriasis may develop psoriatic arthritis (PsA). Subclinical inflammatory joint disease in patients with psoriasis is common. i,ii This study…
  • Abstract Number: 2769 • 2016 ACR/ARHP Annual Meeting

    Does Gender Make a Difference in “Composite Psoriatic Disease Activity Index (CPDAI)” in Patients with Psoriatic Arthritis?

    Gokce Kenar1, Handan Yarkan2, Berrin Zengin1, Gerçek Can2, Merih Birlik1, Nurullah Akkoc1 and Fatos Onen1, 1Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, 2Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey

    Background/Purpose:  “Composite psoriatic disease activity index (CPDAI)” includes 5 domains: peripheral joints, skin, enthesitis, dactylitis, and spinal manifestations in psoriatic arthritis (PsA) which is a…
  • Abstract Number: 1665 • 2016 ACR/ARHP Annual Meeting

    Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease

    Remy Pollock1, Laila Zaman1, Vinod Chandran2 and Dafna D Gladman3, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

    Background/Purpose:  Heritable epigenetic phenomena may play a role in the parent-of-origin effect observed in psoriasis and psoriatic arthritis (PsA). A previous epigenome-wide association study (EWAS)…
  • Abstract Number: 3035 • 2016 ACR/ARHP Annual Meeting

    Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease

    Yahui Grace Chiu1, Edward Schwarz2, Richard Bell3, Dongge Li4, Nelson Huertas4, Cristy Bell5, Sharon Moorehead5, Debbie Campbell5, Changyong Feng6 and Christopher T. Ritchlin7, 1Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Orthopedeatrics, University of Rochester, Rochester, NY, 3Pathology, University of Rochester, Rochester, NY, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, 6Statistics, University of Rochester, Rochester, NY, 7Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease that affects over 650,000 Americans. Bone damage occurs in half of these patients within the first…
  • Abstract Number: 1684 • 2016 ACR/ARHP Annual Meeting

    Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study

    Christopher T. Ritchlin1, Alan Menter2, Philip J Mease3, Sunil Kalia4, Francisco Kerdel5, Shelly Kafka6, James Morgan6, Wayne Langholff7, Steve Fakharzadeh6, Kavitha Goyal6 and Alice Gottlieb8, 1Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Baylor Research Institute, Dallas, TX, 3Swedish Medical Center and University of Washington, Seattle, WA, 4University of British Columbia, Vancouver, BC, Canada, 5University of Miami, Miami, FL, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Research & Development, LLC, Spring House, PA, 8Tufts University School of Medicine (affiliation at the time of the study), Boston, MA

    Background/Purpose: To describe the rates of serious infections (SI) in psoriasis (PsO) pts with psoriatic arthritis (PsA) from PSOLAR, & assess risk with biologic therapy.…
  • Abstract Number: 3185 • 2016 ACR/ARHP Annual Meeting

    Sensitivity Analysis for the Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients

    Uyen-Sa D.T. Nguyen1,2, Yuqing Zhang2, David T. Felson2,3,4, Michael P. Lavalley5 and Hyon K. Choi6, 1Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, 2Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 3Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 4Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, 5Biostatistics, Boston University School of Public Health, Boston, MA, 6Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Smoking is a strong risk factor for psoriasis and psoriatic arthritis, but several studies have found that smoking is inversely associated with the risk…
  • Abstract Number: 1685 • 2016 ACR/ARHP Annual Meeting

    Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study

    Philip J Mease1, Alice Gottlieb2, Alan Menter3, Christopher T. Ritchlin4, Sunil Kalia5, Francisco Kerdel6, Shelly Kafka7, Soumya Chakravarty7, Wayne Langholff8, Steve Fakharzadeh7, Kavitha Goyal7 and Jose U. Scher9,10, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Tufts University School of Medicine (affiliation at the time of the study), Boston, MA, 3Baylor Research Institute, Dallas, TX, 4Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, 5University of British Columbia, Vancouver, BC, Canada, 6University of Miami, Miami, FL, 7Janssen Scientific Affairs, LLC, Horsham, PA, 8Janssen Research & Development, LLC, Spring House, PA, 9New York University School of Medicine, New York, NY, 10Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: To describe characteristics & potential risk factors(including treatment exposure) for all-cause mortality & malignancies (excluding NMSC) in psoriasis (PsO) patients (pts) with psoriatic arthritis…
  • Abstract Number: 1686 • 2016 ACR/ARHP Annual Meeting

    Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab

    Diamant Thaci1, Akimichi Morita2, Julie Birt3, Chen-Yen Lin3, Catherine L. Shuler3 and Alice B. Gottlieb4, 1Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, 2Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 3Eli Lilly and Company, Indianapolis, IN, 4Tufts University School of Medicine, Boston, MA

    Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. In a phase 3 study, IXE was superior to placebo (PBO) in achieving…
  • Abstract Number: 1708 • 2016 ACR/ARHP Annual Meeting

    Cutaneous Microbiota Features Distinguish Psoriasis from Psoriatic Arthritis

    Julia Manasson1, Soumya M. Reddy1, Andrea L. Neimann2, Leopoldo N. Segal3 and Jose U. Scher1, 1Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Department of Dermatology, New York University School of Medicine, New York, NY, 3Department of Medicine, Division of Pulmonary and Critical Care, New York University School of Medicine, New York City, NY

    Background/Purpose:   Psoriasis (PsO) is a chronic immune-mediated skin condition affecting ~3% of adults worldwide. Up to a third of PsO patients go on to…
  • Abstract Number: 1716 • 2015 ACR/ARHP Annual Meeting

    Prevalence of Joint Symptoms and Frequency of Joint Exams for Patients with Plaque Psoriasis without Confirmed Psoriatic Arthritis: A US Analysis

    Tatiana Makhinova1, Robert Wood2, Derek Tang3, James Piercy2, Steve Lobosco4, Bradley S. Stolshek5 and David J. Harrison5, 1College of Pharmacy, University of Texas at Austin, Austin, TX, 2Adelphi Real World, Macclesfield, United Kingdom, 3Amgen, Inc., Thousand Oaks, CA, 4Adelphi Real World Ltd., Macclesfield, United Kingdom, 5Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Due to the high prevalence of PsA among patients with PsO,1 rheumatologists and dermatologists should recognize early signs and symptoms of joint involvement among…
  • Abstract Number: 2144 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis

    Kim Papp1, Alan Menter2, Howard Sofen3, Stephen Tyring4, Jean-Philippe Lacour5, Beate Berner6, Nathan Bennett7, Stella Aslanyan7, Mary Flack7 and Paul Scholl7, 1Probity Clinical Research, Waterloo, ON, Canada, 2Baylor Research Institute, Dallas, TX, 3Dermatology Research Associates, Los Angeles, CA, 4Center for Clinical Studies, Houston, TX, 5Dermatology Department, Hôpital de L’Archet, Nice, France, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 7Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

     Background/Purpose: IL-23 is essential for the differentiation and maintenance of Th17 cells in psoriasis and psoriatic arthritis (PsA). We assessed the efficacy and safety of…
  • Abstract Number: 2519 • 2015 ACR/ARHP Annual Meeting

    Pregnancy in Psoriatic Arthritis: A Case Series

    Maria Mouyis1, Clare Thornton1, David Williams2,3 and Ian Giles4, 1Rheumatology, University College London Hospital, London, United Kingdom, 2Institute for Women’s Health, University College London, London, United Kingdom, 3University College London, London, United Kingdom, 4Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom

    Background/Purpose: It is recognised that active disease in women with inflammatory arthritis is associated with adverse pregnancy outcomes. Most studies however, have focussed upon patients…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology